The Medicines Company: (NASD: MDCO)

$33.48

0.95 (2.92%)

Volume 1,093,134

May 23 02:10 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		31.31 - 33.64
	
		52wk Low - High
		20.04 - 37.40
	
		Previous Close
		32.53
	
		Avg. Volume
		1,149,398
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		1.75 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.81
	
		PE (Forward)
		34.83
	
		Current Year Est.
		0.93
	
		Quarterly Earnings ESP 
		-3.23%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		95 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/29/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            34.83
                        
                            PEG Ratio
                            1.93
                        
                            Current Year Est.
                            0.93
                        
                            Current Quarter Estimate
                            0.31
                        
                            Most Accurate Estimate
                            0.30
                        
                            Earnings ESP 
                            -3.23%
                        
                            Next Earnings Report Date
                            07-24-2013
                        
                            EPS Last Year
                            1.69
                        
                            Expected Earnings Growth
                            18.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty.  The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.   
Full MDCO Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
MDCO Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.31	0.36	0.93	1.59
Number of Estimates	5	4	5	5
Low Estimate	0.29	0.30	0.76	0.84
High Estimate	0.34	0.40	1.04	NA
Year Ago EPS	0.39	0.33	1.64	0.93
EPS Growth	-21.54%	9.85%	-43.05%	70.24%

More MDCO Estimates

Average Earnings Estimates for MDCO

EPS Growth for MDCO

Industry Analysis

Name	Symbol	Previous Close
MEDICINES CO	MDCO	32.53
AETERNA ZENTARS	AEZS	2.06
ANIKA THERAPEUT	ANIK	13.75
GENTIUM SPA-ADR	GENT	8.79
AASTROM BIOSCI	ASTM	0.57
ACADIA PHARMA	ACAD	13.42
ACHILLION PHARM	ACHN	7.74
ADDEX THERA LTD	ADDXF	6.62
AFFYMAX INC	AFFY	1.40
ALEXION PHARMA	ALXN	100.57

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Pediatric Approval for MDCO/BMY's Recothrom

May 15, 2013

Earnings Increase at The Medicines Co.

Apr 26, 2013

MDCO's Cangrelor Impresses

Mar 11, 2013

Encouraging News for Cubist Pharma

Mar 01, 2013

4Q Beat for The Medicines Co.

Feb 22, 2013

MDCO-BMY Deal Comes into Effect

Feb 11, 2013

Alnylam-MDCO Join for ALN-PCS

Feb 05, 2013

The Medicines Co. Acquires Incline

Jan 11, 2013

More MDCO Zacks Commentary

Financials

EPS TTM	1.69
Sales	559
Net Income	32
Price/Earnings	19.25
Price/Book	2.86
Price/Cash Flow	16.74
Price/Sales	2.98

More MDCO Financials

News

Analysis of Relative Performance in the Pharmaceuticals Industry for Shares of Nektar Therapeutics (NKTR, CADX, MDCO, QCOR, TEVA) - Financial News Network Online - News Corner

May 23, 2013

Is There a Future for Small Pharma? - TheMotleyFool

May 23, 2013

Lumber Liquidators Leads Top 5 Small Cap Screen - Investors Business Daily

May 23, 2013

Medicines Co Makes a Move: Up 2.3% - Financial News Network Online - Market Movers

May 23, 2013

Stocks Ease To Mild Losses: Dollar Tree, HP Add Gains - Investors Business Daily

May 23, 2013

Stocks Stage Broad Advance; Bristol-Myers Leads Medicals - Investors Business Daily

May 22, 2013

Medicines Co Set to Possibly Rebound After Yesterday's Selloff of 5.34% - Comtex Smartrend(R)

May 21, 2013

Sellers Reduce Exposure to Shares of Medicines Co on 3.2x Above-Average Volume (MDCO) - Financial News Network Online - Unusual Volume

May 21, 2013

See All News Stories on MDCO

Broker Recommendations

Current ABR	1.50
ABR (Last Week)	1.50
# of recs in ABR	6
Average Target Price	37.92
Industry Rank by ABR	95 out of 265
Rank in Industry	36 out of 152

More MDCO Broker Recommendations

Day Low - High	31.31 - 33.64
52wk Low - High	20.04 - 37.40
Previous Close	32.53
Avg. Volume	1,149,398
Industry	MED-BIOMED/GENE
Market Cap	1.75 B
Div - Yield	0.00 - 0.00
Beta	0.81
PE (Forward)	34.83
Current Year Est.	0.93
Quarterly Earnings ESP	-3.23%

PE (Forward)	34.83
PEG Ratio	1.93
Current Year Est.	0.93
Current Quarter Estimate	0.31
Most Accurate Estimate	0.30
Earnings ESP	-3.23%
Next Earnings Report Date	07-24-2013
EPS Last Year	1.69
Expected Earnings Growth	18.00%

Username: Password:

Remember me [?]

The Medicines Company: (NASD: MDCO)

$33.48

0.95 (2.92%)

Volume 1,093,134

May 23 02:10 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations